A new study presented at the Academy of Managed Care Pharmacy's 22nd Annual Meeting finds that one in six cancer clients with high out-of-pocket (OOP) costs abandons their medication. The study by Prime Therapeutics (Prime), a thought leader in pharmacy benefit management, found profession with an OOP cost greater than $200 were at least three times more likely to not fill their prescript than those with OOP costs of $100 or less. The study suggests higher OOP costs for these oncology medications may negatively impact patient health as well as long-term health care costs. While only 4...

More: - Continued here